The 18th Biosimilar Medicines Conference covers topics such as:
- Biosimilars: the European Commission industrial policy strategy and "Tajani initiative" follow-up
- Biological and biosimilar medicines market: current status and future outlook
- Biosimilars uptake: best practice sharing by key EU member states
- Biosimilars evolving landscape: insight into market access
- Real World Evidence sharing
- Debate on GfK study findings: a multi-stakeholder approach in support of the biosimilar medicines market sustainability
- Biosimilars naming and labelling regime: the European experience
- The science of extrapolation of indications, explained by EU regulators
- Biosimilar medicines approvals and scientific guidelines latest developments: the EMA overview
- WHO Biological Qualifier Scheme: status of the proposal
- Biosimilars: news from the US/FDA
- Biosimilars global development: the role of WHO and National Drug Regulatory Authorities
- The biosimilarity concept: bringing it closer to patients, healthcare professionals and medical societies
The 18th Biosimilar Medicines Conference brings together International Regulators, leading EU and Experienced EU Companies.